Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Allison Berger"'
Autor:
Evan F. Lind, Vi Lam, Nathan D. Pennock, Scott R Best, Adam Kittai, Alexey V. Danilov, Nur Bruss, Allison Berger, Susan E. Murray, Tingting Liu, Olga V. Danilova
Publikováno v:
Leukemia
Novel targeted agents used in therapy of lymphoid malignancies, such as inhibitors of B-cell receptor-associated kinases, are recognized to have complex immune-mediated effects. NEDD8-activating enzyme (NAE) has been identified as a tractable target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcae410fe576a9e2b7a646012b4569dc
https://europepmc.org/articles/PMC8288064/
https://europepmc.org/articles/PMC8288064/
Autor:
Neil MacLean, Shawn Brennan, Adam C. Smith, Rose Hurren, Allison Berger, Xiaoming Wang, Razq Hakem, Marcela Gronda, Mark D. Minden, Sara Farshchi Zarabi, Simon Kavanagh, Tary Traore, G. Wei Xu, Aaron D. Schimmer, Emil F. Pai, Samir H. Barghout, Ondrej Halgas, Michael Milhollen, Marc L. Hyer, Parasvi S. Patel, Danny V. Jeyaraju
Publikováno v:
Leukemia. 33:37-51
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy for which new therapeutic approaches are required. One such potential therapeutic strategy is to target the ubiquitin-like modifier-activating enzyme 1 (UBA1), the initiating enzyme
Autor:
J. Claire Godbersen, Christopher George Danes, Taylor Rowland, Alexey V. Danilov, Cody Paiva, Allison Berger, Olga V. Danilova
Publikováno v:
Oncotarget
// Cody Paiva 1, * , J. Claire Godbersen 2, * , Taylor Rowland 1 , Olga V. Danilova 3 , Christopher Danes 4 , Allison Berger 4 , Alexey V. Danilov 1 1 Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA 2 Geisel School of
Autor:
Todd M. Pitts, Alice McDonald, John J. Tentler, Aik Choon Tan, Kit Man Wong, Peter G Smith, Peter J. Klauck, Stacey M. Bagby, S. Gail Eckhardt, Anna Spreafico, Heather M. Selby, Stephen J. Blakemore, Allison Berger, Lindsey N. Micel
Publikováno v:
Investigational New Drugs. 35:11-25
Background The neddylation pathway conjugates NEDD8 to cullin-RING ligases and controls the proteasomal degradation of specific proteins involved in essential cell processes. Pevonedistat (MLN4924) is a selective small molecule targeting the NEDD8-ac
Autor:
Craig Okada, Alexey V. Danilov, Nur Bruss, Allison Berger, Cody Paiva, Tingting Liu, Adam Kittai, Scott R Best, Taylor Hashiguchi
Publikováno v:
Blood advances. 3(1)
Alterations in the ubiquitin proteasome system (UPS) leave malignant cells in heightened cellular stress, making them susceptible to proteasome inhibition. However, given the limited efficacy of proteasome inhibitors in non-Hodgkin lymphoma (NHL), no
Autor:
Kathryn A. Rizzo, Steven Grant, Sri Lakshmi Chalasani, Lawrence F. Povirk, Liang Zhou, Yun Dai, Mohamed Rahmani, Allison Berger, Andrea Ferreira-Gonzalez, Lihong Li, Hui Lin, Catherine I. Dumur, Yun Leng, Shuang Chen, Maciej Kmieciak, Yu Zhang
Publikováno v:
Blood. 127:2219-2230
Two classes of novel agents, NEDD8-activating enzyme (NAE) and histone deacetylase (HDAC) inhibitors, have shown single-agent activity in acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS). Here we examined mechanisms underlying interact
Autor:
Glen J. Weiss, John S. Kauh, Bruce J. Dezube, Jeffrey W. Clark, Roger B. Cohen, Devalingam Mahalingam, James M. Cleary, Hélène M. Faessel, Allison Berger, Michael D. Pickard, George Mulligan, Kristin E. Burke, R. Donald Harvey, Geoffrey I. Shapiro, John Sarantopoulos
Publikováno v:
Clinical Cancer Research. 22:847-857
Purpose: To determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) and to investigate pevonedistat pharmacokinetics and pharmacodyna
Autor:
Steve Stroud, Jade Lyons Rimmer, Emanuela Ercolano, David A Hilton, Claire L. Adams, Allison Berger, C. Oliver Hanemann, Mahindra Makhija, Daniele Baiz, Sells Todd B
Publikováno v:
Cancers
Volume 12
Issue 7
Cancers, Vol 12, Iss 1744, p 1744 (2020)
Volume 12
Issue 7
Cancers, Vol 12, Iss 1744, p 1744 (2020)
Meningioma is the most common primary intracranial tumour, and surgical resection is the main therapeutic option. Merlin is a tumour suppressor protein that is frequently mutated in meningioma. The activity of the E3 ubiquitin ligase complex, CRL4-DC
Autor:
Dennis Huszar, Allison Berger, Alejandro Gomez-Pinillos, Mi-Sook Kim, Amitkumar Mehta, Igor Proscurshim, Chirag Patel, Paolo Caimi, Bingxia Wang, Sarit Assouline, Sharon Friedlander
Publikováno v:
Blood. 134:1593-1593
Background TAK-981 is a first-in-class, small molecule inhibitor of SUMOylation, a reversible post-translational modification that regulates protein function by covalent attachment of small ubiquitin-like modifier (SUMO) proteins to a protein substra
Autor:
Kristina Xega, Michael Milhollen, Dennis Huszar, Erik Koenig, Eric S. Lightcap, Vaishali Shinde, Stephen Grossman, Keli Song, Sharon Friedlander, Omid Ghasemi, Allison Berger, Pooja Shah, Gary Shapiro, Agatha Zawadzka
Publikováno v:
Cancer Research. 79:3079-3079
TAK-981 is a small molecule inhibitor of the SUMOylation enzyme cascade which is currently in a Phase I clinical trial (NCT03648372). TAK-981 selectively inhibits the activity of the SUMO activating enzyme, forming a covalent adduct between TAK-981 a